Assembly Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASMB Nasdaq 2836 www.assemblybio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Assembly Biosciences, Inc.

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 - Apr 9th, 2026 6:00 am
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates - Mar 19th, 2026 3:20 pm
Assembly Biosciences: Q4 Earnings Snapshot - Mar 19th, 2026 2:26 pm
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights - Mar 19th, 2026 2:05 pm
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates - Mar 5th, 2026 3:30 pm
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates - Feb 26th, 2026 3:30 pm
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates - Feb 24th, 2026 7:55 pm
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors - Dec 24th, 2025 4:20 am
GILD Exercises Option to License Assembly Bio's Herpes Programs - Dec 23rd, 2025 8:45 am
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Dec 22nd, 2025 6:00 am
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes - Dec 8th, 2025 2:05 pm
Assembly Biosciences, Inc.'s (NASDAQ:ASMB) Shift From Loss To Profit - Dec 3rd, 2025 9:57 am
Here's Why We're Not At All Concerned With Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Situation - Nov 13th, 2025 3:08 am
Assembly Biosciences: Q3 Earnings Snapshot - Nov 10th, 2025 2:18 pm
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - Nov 10th, 2025 2:05 pm
US Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Biosciences, Wacker Chemie, Quay Pharmaceuticals, NIZO, Lonza, Inpac Probiotics - Nov 10th, 2025 7:40 am
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - Nov 7th, 2025 6:00 am
Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates - Nov 4th, 2025 3:20 pm
H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data - Oct 29th, 2025 9:57 am
Assembly Biosciences Announces Upcoming Investor Conference Participation - Oct 14th, 2025 5:00 am